COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

Dan Zhou, Sheng-Ming Dai, Qiang Tong, Dan Zhou, Sheng-Ming Dai, Qiang Tong

Abstract

A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept across 31 provinces in China and over 40 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release. There is an urgent need to identify safe and effective drugs for treatment. Chloroquine (CQ) exhibits a promising inhibitory effect. However, the clinical use of CQ can cause severe side effects. We propose that hydroxychloroquine (HCQ), which exhibits an antiviral effect highly similar to that of CQ, could serve as a better therapeutic approach. HCQ is likely to attenuate the severe progression of COVID-19, inhibiting the cytokine storm by suppressing T cell activation. It has a safer clinical profile and is suitable for those who are pregnant. It is cheaper and more readily available in China. We herein strongly urge that clinical trials are performed to assess the preventive effects of HCQ in both disease infection and progression.

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
The chemical structures of CQ and HCQ.
Figure 2.
Figure 2.
A graphical illustration of the antiviral mechanisms of CQ and HCQ. Both chemicals can interfere with the glycosylation of ACE2 and reduce the binding efficiency between ACE2 on the host cells and the spike protein on the surface of the coronavirus. They can also increase the pH of endosomes and lysosomes, through which the fusion process of the virus with host cells and subsequent replication are prevented. When HCQ enters APCs, it prevents antigen processing and MHC class II-mediated autoantigen presentation to T cells. The subsequent activation of T cells and expression of CD154 and other cytokines are repressed. In addition, HCQ disrupts the interaction of DNA/RNA with TLRs and the nucleic acid sensor cGAS and therefore the transcription of pro-inflammatory genes cannot be stimulated. As a result, administration of CQ or HCQ not only blocks the invasion and replication of coronavirus, but also attenuates the possibility of cytokine storm. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.

References

    1. Xu X, Chen P, Wang J. et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020; 63: 457–60.
    1. Wang D, Hu B, Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; doi:10.1001/jama.2020.1585.
    1. Shimabukuro-Vornhagen A, Godel P, Subklewe M. et al. Cytokine release syndrome. J Immunother Cancer 2018; 6: 56.
    1. Wang M, Cao R, Zhang L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269–71.
    1. Sheahan TP, Sims AC, Graham RL. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9: eaal3653.
    1. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P. et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20–8.
    1. Lotteau V, Teyton L, Peleraux A. et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990; 348: 600–5.
    1. Wu SF, Chang CB, Hsu JM. et al. Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. Arthritis Res Ther 2017; 19: 183.
    1. van den Borne BE, Dijkmans BA, de Rooij HH. et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 1997; 24: 55–60.
    1. Kuznik A, Bencina M, Svajger U. et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186: 4794–804.
    1. Ewald SE, Lee BL, Lau L. et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008; 456: 658–62.
    1. Hacker H, Mischak H, Miethke T. et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998; 17: 6230–40.
    1. Vollmer J, Tluk S, Schmitz C. et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005; 202: 1575–85.
    1. An J, Woodward JJ, Sasaki T. et al. Cutting edge: antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction. J Immunol 2015; 194: 4089–93.
    1. Vincent MJ, Bergeron E, Benjannet S. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2: 69.
    1. Millet JK, Whittaker GR.. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res 2015; 202: 120–34.
    1. Schrezenmeier E, Dorner T.. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020; 16: 155–66.
    1. Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect 2017; 5: e00293.
    1. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I. et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009; 11: R109.
    1. Srinivasa A, Tosounidou S, Gordon C.. Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue? J Rheumatol 2017; 44: 398.
    1. Jorge A, Ung C, Young LH. et al. Hydroxychloroquine retinopathy—implications of research advances for rheumatology care. Nat Rev Rheumatol 2018; 14: 693–703.
    1. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN. et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126: 76–82.
    1. Lisney AR, Szelinski F, Reiter K. et al. High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block. Ann Rheum Dis 2017; 76: 1476–80.
    1. Furst DE, Lindsley H, Baethge B. et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum 1999; 42: 357.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit